BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Real-world effectiveness of oral antiviral treatment for COVID-19 
 in Hong Kong - Carlos Wong
DTSTART:20231025T130000Z
DTEND:20231025T140000Z
UID:TALK207718@talks.cam.ac.uk
CONTACT:Paula Smith
DESCRIPTION:Oral antivirals\, molnupiravir and nirmatrelvir/ritonavir\, ha
 ve been used in patients with SARS-CoV-2 infection to reduce the risks of 
 severe disease and mortality\, and hence to reduce the burden on health-ca
 re systems. In early 2022\, published clinical trials were conducted in un
 vaccinated\, non-hospitalised patients with mild-to-moderate COVID-19 duri
 ng the SARS-CoV-2 delta variant\, while evidence on real-world effectivene
 ss of oral antivirals in patients infected with Omicron variant was scarce
 . This seminar will present the findings of two real-world studies examine
  the effectiveness of molnupiravir and nirmatrelvir/ritonavir in hospitali
 sed patients and community-dwelling patients with SARS-CoV-2 during a pand
 emic wave dominated by omicron BA.2.2 in Hong Kong\, China.  \n\nShort Bio
 : Carlos Wong is currently Senior Research Director of the Laboratory of D
 ata Discovery for Health (D24H)\, and Honorary Assistant Professor at The 
 University of Hong Kong. He received his Bachelor and MPhil degrees from D
 epartment of Mathematics at Hong Kong University of Science and Technology
 \, and obtained his PhD at Faculty of Medicine\, The University of Hong Ko
 ng. He has been studying and working at the University of Hong Kong since 
 2008\, and was Assistant Professor before the move to the UK. His research
  interests are pharmacoepidemiology and pharmacovigilance\, using the rout
 inely-collected electronic health record databases. \n
LOCATION:Zoom
END:VEVENT
END:VCALENDAR